secwatch.observer — SEC 8-K summary
======================================

Issuer:     MapLight Therapeutics, Inc. (MPLT)
CIK:        0001770069
Form:       8-K
Filed at:   2026-05-14T20:15:32+00:00
Accession:  0001193125-26-224067
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MapLight Therapeutics Q1 net loss $60.7M; completes enrollment in two Phase 2 trials
--------------------------------------------------------------------------------

- Net loss of $60.7M in Q1 2026 vs $22.3M YoY; R&D expenses $53.7M, G&A $10.8M.
- Cash and investments $395.2M as of March 31, 2026; expected to fund operations through 2027.
- Enrollment completed in Phase 2 ZEPHYR trial (schizophrenia, n=307); topline data expected mid-August 2026.
- Last patient visit completed in Phase 2 IRIS trial (autism, n=161); topline data also expected mid-August 2026.
- Phase 2 VISTA trial for Alzheimer's disease psychosis ongoing; topline expected H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/0001193125-26-224067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/mplt-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer